Verastem (VSTM) Amortization of Deferred Charges (2017 - 2026)
Verastem (VSTM) recorded quarterly Amortization of Deferred Charges of -$119000.0 in Q1 2026, down 11800.0% quarter-over-quarter from -$1000.0 in Q2 2025, and down 496.67% on a YoY basis from $30000.0 in Q1 2025.
Verastem (VSTM) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Verastem's Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at -$119000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 496.67% year-over-year to -$119000.0; the TTM figure through Mar 2026 stood at -$120000.0 (down 127.03% YoY), while the FY2025 annual figure was $29000.0, up 680.0% from the prior year.
- Amortization of Deferred Charges was -$119000.0 for Q1 2026 at Verastem, down from -$1000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $207000.0 in Q4 2024 to a low of -$837000.0 in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged -$66600.0 across 5 years, with a median of $6000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges plunged 27800.0% in 2023, then soared 154.18% in 2024.
- A 5-year view of Amortization of Deferred Charges shows it stood at -$3000.0 in 2022, then slumped by 27800.0% to -$837000.0 in 2023, then soared by 124.73% to $207000.0 in 2024, then plunged by 100.48% to -$1000.0 in 2025, then sank by 11800.0% to -$119000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at -$119000.0 (Q1 2026), -$1000.0 (Q2 2025), and $30000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119,000.00 |
| Mar 31, 2026 | -119,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 207,000.00 |
| Dec 31, 2024 | 207,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | -419,000.00 |
| Mar 31, 2024 | -419,000.00 |
| Dec 31, 2023 | -837,000.00 |
| Dec 31, 2023 | -837,000.00 |
| Sep 30, 2023 | -371,000.00 |
| Sep 30, 2023 | -371,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Jun 30, 2023 | 112,000.00 |